ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

Rosen Law Firm is soliciting investors in Atara Biotherapeutics who purchased securities between May 20, 2024 and January 9, 2026 to join a class action lawsuit. The lawsuit alleges that Atara made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, and that regulatory prospects were overstated. The lead plaintiff deadline is May 22, 2026.